In Issue 10 of Malignant Haematology Research Review:
- Venetoclax or placebo in combination with bortezomib
and dexamethasone in relapsed or refractory multiple
myeloma (BELLINI) - Belantamab mafodotin plus bortezomib and
dexamethasone in patients with relapsed or
refractory multiple myeloma (DREAMM-7) - Isatuximab, carfilzomib, lenalidomide,
and dexamethasone induction in newly
diagnosed myeloma